Cellectar Biosciences, Inc. ã¯èšåºãã€ãªå»è¬åäŒæ¥ã§ãããããæ²»çè¬ã®çºèŠãéçºãåååã«æ³šåããŠããŸããå瀟ã®äž»åãªã³è質è¬ç©è€åäœ (PDC) åè£ã¯ CLR 131 ã§ãåçºæ§ãŸãã¯é£æ²»æ§ (R/R) ã¯ã«ãã³ã·ã¥ãã¬ãŒã ãã¯ãã°ãããªã³è¡ç (WM) ããã³ B çŽ°èæªæ§è
«çã®æ£è
ã察象ã«ç¬¬ II çžèšåºè©Šéšãé²è¡äžã§ãããŸããr/r å€çºæ§éªšé«è
« (MM) æ£è
ã察象ã«ç¬¬ IIB çžèšåºè©Šéšãé²è¡äžã§ããããã«ãããŸããŸãªå°å
ãããR/R é é žéšãããR/R MM ã察象ã«ç¬¬ I çžèšåºè©Šéšãé²è¡äžã§ããå瀟ã¯ãŸããåºåœ¢è
«çãæ²»çããããã®åèšåºæ®µéã«ãã PDC ååŠçæ³ããã°ã©ã CLR 1900 ãéçºããŠããŸããå瀟㯠Avicenna Oncology GMBH ãšå
±åã§ CLR 2000 ã·ãªãŒãºãéçºCellectar Biosciences, Inc. 㯠2002 幎ã«èšç«ããããã¥ãŒãžã£ãŒãžãŒå·ãããŒã©ã ããŒã¯ã«æ¬ç€Ÿã眮ããŠããŸãã